Overview

Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Status:
Completed

Trial end date:
2018-07-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

PRA Health Sciences

Treatments:

Antibodies, Monoclonal